A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice

Cutts, C., La Caze, A. and Tett, S. E. (2002) A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice. British Journal of Clinical Pharmacology, 54 5: 522-527.


Author Cutts, C.
La Caze, A.
Tett, S. E.
Title A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice
Journal name British Journal of Clinical Pharmacology   Check publisher's open access policy
ISSN 0306-5251
Publication date 2002
Sub-type Article (original research)
DOI 10.1046/j.1365-2125.2002.01666.x
Volume 54
Issue 5
Start page 522
End page 527
Total pages 6
Editor M. S. Lennard
J. M. Ritter
E. J. Begg
Place of publication UK
Publisher Blackwell Science
Collection year 2002
Language eng
Subject C1
321028 Rheumatology and Arthritis
730209 Rural health
Abstract Aims The new cyclooxygenase-2 (COX-2) selective inhibitors, celecoxib (Celebrex®) and rofecoxib (Vioxx®), have been widely prescribed since their launch. No reviews currently appear in the literature of prescribing patterns in Australia. This paper describes a self-audit of the clinical use of selective COX-2 inhibitor therapy undertaken with rural general practitioners (GPs) in Australia. Methods A structured audit form was developed and distributed to interested GPs. The form was self-administered and focused on issues about COX-2 inhibitors and the types of patients who were receiving them, e.g. indications, patient demographics, risk factors and drug interactions. Results A total of 627 patients were recruited (569 celecoxib and 58 rofecoxib). A range of doses was prescribed. Osteoarthritis was the most common indication (68.1%). Risk factors known for the nonselective nonsteroidal anti-inflammatory drugs were identified in 65.1% of patients, with the most common being advanced age, hypertension and previous peptic ulcer disease. Potential drug interactions were common. A variety of reasons for initiation of therapy was identified; these included perceived increased efficacy, safety and failure of other treatment. Conclusions These results show that COX-2 inhibitors are being prescribed for patients with multiple risk factors that may place the patient at increased risk of adverse drug reactions to a COX-2 inhibitor. The perception of improved safety and efficacy was common and is of concern. Limitations of the study include the reliance on self-reporting.
Keyword Australia
rural general practitioners
inhibitor therapy
celecoxib
rofecoxib
Pharmacology & Pharmacy
Audit
Cox-2 Inhibitor
Nsaid
Nonsteroidal Antiinflammatory Drugs
Randomized Controlled Trial
Rheumatoid-arthritis
Gastrointestinal Toxicity
Renal-failure
Triple Whammy
Osteoarthritis
Therapy
Q-Index Code C1

Document type: Journal Article
Sub-type: Article (original research)
Collections: Excellence in Research Australia (ERA) - Collection
School of Pharmacy Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 11 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 18 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Access Statistics: 241 Abstract Views  -  Detailed Statistics
Created: Tue, 14 Aug 2007, 18:21:06 EST